To explore the association between the relative expression level of SNORD55 in peripheral blood and the outcomes of all-cause mortality and stroke in patients with atrial fibrillation (AF), and to evaluate the predictive value of SNORD55 for prognosis.

A total of 133 patients with non-valvular AF admitted in Department of Cardiology of the First Affiliated Hospital of Army Medical University from January 2014 to December 2017 were enrolled in this study. Their baseline information was collected, and the relative expression level of plasma SNORD55 was detected. Cox proportional hazards model was used to explore the association between the relative expression level of SNORD55 in peripheral blood and all-cause mortality as well as stroke in the patients. The predictive performance of CHA₂DS₂-VASc score for all-cause mortality and stroke was compared with the score combined with the relative expression level of SNORD55 in the AF patients. The area under the receiver operating characteristic curve (AUC) was utilized to evaluate the discrimination, and the net reclassification index (NRI) and comprehensive discriminant improvement index (IDI) were calculated to evaluate the improvement of reclassification ability. Decision curve analysis (DCA) was applied to analyze the change in clinical net benefit.

The results of multivariate Cox regression showed that high expression of SNORD55 in peripheral blood was an independent risk factor for all-cause mortality and stroke in the AF patients. In predicting the outcomes of all-cause mortality and stroke, the addition of relative expression SNORD55 level with the CHA₂DS₂-VASc score obtained higher AUC value [0.80 (95%CI: 0.67~0.93) vs 0.67 (95%CI: 0.53~0.81), P<0.05]. In predicting the outcome of all-cause death and stroke, combination of the relative expression level of SNORD55 with CHA2DS2-VASc score increased both NRI [54.3 (95%CI: 10.6~61.9) vs 31.9 (95%CI: 2.8~47.5), P<0.05] and IDI [16.1 (95%CI: 2.4~27.0) vs 7.9 (95%CI: 0.5~14.8), P<0.05]. The results of DCA showed that our combination of CHA₂DS₂-VASc score relative expression level of SNORD55 had higher clinical net benefits than the foreign ABC score in the prediction of the outcomes.

Peripheral blood SNORD55 level is an independent risk factor for all-cause mortality and stroke in AF patients, and has good predictive performance for all-cause mortality and stroke in the patients.

To explore the association of peripheral blood PIWI-interacting RNA, piR-hsa-2700592, with all-cause mortality and stroke outcomes in patients with atrial fibrillation (AF), and to determine whether piR-hsa-2700592 has the potential to be an AF biomarker.

A total of 127 patients with non-valvular AF were enrolled, and the relative expression level of plasma piR-hsa-2700592 was detected. Cox proportional hazard regression was used to analyze the correlation between the expression of piR-hsa-2700592 and all-cause death as well as stroke outcome in the patients. Then the molecule expression level was combined with CHA₂DS₂-VASc score and ABC stroke (or death) score to establish 2 new prediction models, the improvement of the predictive performance was compared and analyzed. Receiver operating characteristic (ROC) curve analysis (area under the curve, AUC), net reclassification index (NRI), and comprehensive discriminant improvement index (IDI) were used to evaluate the predictive performance, and decision curve analysis (DCA) was employed to assess the clinical benefit.

Multivariate Cox regression analysis showed that the patients with higher expression level of piR-hsa-2700592 in peripheral blood had a higher risk of stroke (HR: 2.203, 95%CI: 1.120~4.332; P=0.022). In the stroke outcome, combination of plasma piR-hsa-2700592 expression level with CHA₂DS₂-VASc score and ABC stroke score obtained an AUC of 0.70 (95%CI: 0.55~0.85, P<0.001) and 0.84 (95%CI: 0.73~0.96, P=0.02), respectively. But, no significant association was observed between high plasma piR-hsa-2700592 level and all-cause mortality in the AF patients (HR: 1.997; 95%CI: 0.884~4.509; P=0.096). Combination of plasma piR-hsa-2700592 level improved the discriminative capability than the single CHA₂DS₂-VASc score and ABC stroke score models, with an NRI and IDI value of 44.20% (95%CI: 3.40~59.90, P<0.001) and 8.20% (95%CI: 0.60~15.40, P<0.001), respectively for the new CHA₂DS₂-VASc score model, and an NRI and IDI value of 44.20% (95%CI: 9.80~58.90, P<0.001) and 10.40% (95%CI: 0.70~21.40, P<0.001), respectively for the new ABC stroke score model. The DCA curve showed that both new prediction models obtained better net clinical benefits.

High peripheral blood expression of piR-hsa-2700592 is an independent risk factor for stroke in the AF patients, and the indicator has a good predictive value for prognosis of the patients. piR-hsa-2700592 might be used as a potential biomarker in the diagnosis and prevention of cardiovascular diseases.

To analyze the differential expression profiles of small nucleolar RNAs (snoRNAs) in lung adenocarcinoma and their association with prognosis, screen and validate lung adenocarcinoma-related snoRNAs, and explore their roles in tumorigenesis and progression.

Differentially expressed snoRNAs between lung adenocarcinoma and normal tissues were screened using Arraystar Small RNA expression microarrays. The obtained candidates were validated through the GEO database (GSE261702), followed by selecting snoRNAs that passed molecular cloning experiments, and finally RT-qPCR. By constructing SCARNA4 overexpression models (Vector group and SCARNA4 group) and knockdown models (siNC group and si SCARNA4 group), proliferation, migration and invasion assays were carried out to assess the biological functions of SCARNA4 in lung adenocarcinoma cells. Based on tumor tissues from 108 lung adenocarcinoma patients (Second Affiliated Hospital of Army Medical University, between February 2013 and May 2015), the expression level of SCARNA4 was detected by RT-qPCR. Using X-tile software to determine the optimal cut-off value (3.48), the patients were accordingly stratified into high (57 cases) and low SCARNA4 expression (51 cases) groups. Kaplan-Meier survival curves and Cox proportional hazards regression models were constructed to analyze the impact of SCARNA4 expression on prognosis.

Small RNA microarray identified 62 up-regulated and 4 down-regulated snoRNAs in lung adenocarcinoma tissues. Integration with GEO database and molecular cloning yielded 8 candidate snoRNAs. RT-qPCR results revealed significantly elevated SCARNA4 expression in lung adenocarcinoma tissues than normal tissues (P=0.0427). Overexpression of SCARNA4 significantly promoted the proliferative, migrative, and invasive capacities in A549 cells (P<0.01), whereas its knockdown obviously inhibited these functions (P<0.01). Kaplan-Meier survival analysis demonstrated significantly shorter overall survival in the high-expression group when compared with the low-expression group (P=0.034). Univariate Cox regression analysis further confirmed that high SCARNA4 expression was significantly associated with poor prognosis (HR=2.285, 95%CI: 1.040 to 5.020, P=0.039). Multivariate Cox regression analysis confirmed that, after adjusting for relevant covariates, the expression level of SCARNA4 was an independent risk factor of overall survival of lung adenocarcinoma patients, and its high expression was notably associated with shortened overall survival of patients (HR=3.038, 95%CI: 1.261 to 7.323, P=0.013).

SCARNA4 is up-regulated in lung adenocarcinoma tissues and associated with poor prognosis. It may be involved in the tumorigenesis and development of lung adenocarcinoma by regulating cell proliferation, migration, and invasion. The molecule might hold promise as a novel therapeutic target and prognostic biomarker for lung adenocarcinoma.

To analyze and construct systolic blood pressure (SBP) fluctuation trajectory in a community population with hypertension and to analyze the factors influencing different trajectories.

This is a community-based retrospective cohort study. A latent class trajectory model was used to identify and construct longitudinal trajectories of blood pressure change. Multinomial logistic regression analysis was performed to identify the associated factors of blood pressure trajectories by adjusting for different confounders. Potential confounding factors were identified using a directed acyclic graph based on a priori knowledge.

A total of 793 patients with hypertension were enrolled in the analysis. They were divided into 3 groups by LCTM-fitted systolic blood pressure trajectories, namely stable low-level group (n=561, 70.74%), declining group (n=170, 21.44%) and rising group (n=62, 7.82%). Significant differences were observed among the 3 trajectories groups in terms of age, frequency of exercise, ways of follow-up, salt intake, compliance behavior, and referral (P<0.05). Compared to the stable low-level group and adjusting for corresponding confounding factors, the male patients and the patients with "outpatient follow-up" were more likely to be classified into "declining group", with OR and 95% CI of 1.436 (1.016~2.030) and 1.702 (1.202~2.410), respectively. The participants aged ≥65 years, who did not exercise or occasionally exercised, and had moderate and severe salt intake, were more likely to be classified into the "rising group" (OR=1.949, 2.284, 2.433, 4.540, 95%CI: 1.145~3.317, 1.305~3.998, 1.272~4.654, 1.291~15.963).

SBP trajectories in community-dwelling hypertensive population can be divided into stable low-level, declining and rising groups. Gender, age, salt intake, exercise frequency, and follow-up methods may be influencing factors for SBP blood pressure trajectory.

To construct trajectory models of fasting blood glucose fluctuations in type 2 diabetes mellitus（T2DM）patients in community, and analyze the influencing factors of the trajectory of glucose fluctuation in different categories.

A retrospective cohort study was carried out on 769 T2DM patients who had health records and been involved in the diabetic management in Shuangbei Community Health Service Center of Shapingba District, Chongqing from 2012 to 2019. Group-based trajectory modelling（GBTM）was employed to identify and construct the fluctuation trajectory of fasting blood glucose in the patients. BIC, AvePP and other evaluation indicators were used to select the optimum subgroup number model. Then the differences in demographic characteristics, health status, medical history, lifestyle, medication compliance, etc were compared among different categories. Multinomial logistic regression model was constructed to explore the influencing factors of different fluctuation trajectories.

The 769 T2DM subjects were divided into 3 groups of different fluctuation trajectories by GBTM, that is, low-level steady, high-level falling, and medium-level rising groups. Multinomial logistic regression analysis indicated that the patients with a history of hypertension and not taking medication were less likely to be assigned into the high-level falling group than into the low-level steady group, indicating that their high glucose level was not predisposed to a progressive decline（OR=0.50, 95%CI: 0.28~0.90, P=0.021; OR=0.13, 95%CI: 0.03~0.56, P=0.006）. However, the subjects who occasionally or not exercised, consumed alcohol or abstained from alcohol were more likely to be assigned into the high-level falling group（OR=2.02, 95%CI: 1.15~3.55, P=0.014; OR=2.32, 95%CI: 1.16~4.63, P=0.017）. When compared with the patients with regular medication, those with intermittent medication were more likely to be assigned into the medium-level rising group（OR=6.02, 95%CI: 2.86~12.66, P<0.001）.

There are different trajectories of dynamic changes in fasting glucose for T2DM patients. History of hypertension, medication adherence, frequency of exercise, and alcohol consumption may be associated with different trajectories of blood glucose fluctuations.